Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Pediatric Neurology|November 25, 2010
Failure of a clot retrieval device in an adolescent stroke patientMarcia V Felker, Jennifer A Zimmer, Meredith R Golomb
Pediatric Neurology|September 4, 2007
Age-related variation in presenting signs of childhood arterial ischemic strokeJennifer A Zimmer, Bhuwan P Garg, Linda S Williams, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 7, 2024
How donanemab data address the coverage with evidence development questionsEric G Klein, Krista Schroeder, Alette M Wessels, et al.
Journal of Child Neurology|September 5, 2006
High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggressionDeborah K Sokol, Demao Chen, Martin R Farlow, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|August 5, 2026
Further data to address the Alzheimer's coverage with evidence development questionsMalaz Boustani, Eric G Klein, Jennifer A Zimmer, et al.
Journal of Clinical Pharmacology|December 20, 2019
Clinically Negligible Pharmacokinetic and Pharmacodynamic Interactions Between Lanabecestat and Dabigatran Etexilate, a Prototypical P-gp SubstrateScott A Monk, Alan R Kugler, Scott W Andersen, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 16, 2025
Donanemab exposure-response in early symptomatic Alzheimer's diseaseIvelina Gueorguieva, Kay Chow, Laiyi Chua, et al.
The Journal of Prevention of Alzheimer'S Disease|May 27, 2026
Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analysesFrank Jessen, Grazia Dell'Agnello, Jennifer A Zimmer, et al.
Alzheimer'S & Dementia (New York, N. Y.)|September 4, 2025
Donanemab immunogenicity in participants with early symptomatic Alzheimer's diseaseGarrett R Mullins, Paul Ardayfio, Ivelina Gueorguieva, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 11, 2026
Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trialLars L Raket, Ming Lu, Cynthia D Evans, et al.
Pageof 2